Toxic epidermal necrolysis (TEN)
Also known as: Toxic epidermal necrolysis
Methodology & AI Transparency ⓘ
Toxic epidermal necrolysis (TEN) Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Clinical triage of Toxic epidermal necrolysis (TEN) (also termed Toxic epidermal necrolysis) (L51.2) in Skin & Dermatology relies on or targeted biologics [Toxic epidermal necrolysis (TEN) L51.2], guiding step-wise therapeutic adjustments toward 25-Hydroxy Vitamin D in Toxic epidermal necrolysis (TEN) (L51.2: & hs-CRP) (25(OH)D 40–65 ng/mL (L51.2)).
- 2 Real-world patient consensus: Clinical coding for Toxic epidermal necrolysis (TEN) uses ICD-10 L51.2 across Skin & Dermatology specialty care.
- 3 Typical cash cost range: Differential triage of Toxic epidermal necrolysis (TEN) (L51.2) utilizes or targeted biologics [Toxic epidermal necrolysis (TEN) L51.2].
- 4 Top reported side effects / signs: Follow-up benchmark in Toxic epidermal necrolysis (TEN): maintaining Fasting Lipids & in Toxic epidermal necrolysis (TEN) (L51.2: ALT (if systemic) within Within baseline reference limits (L51.2).
Ask our AI Specialists anything about Toxic epidermal necrolysis (TEN)
What Is Toxic epidermal necrolysis (TEN)?
Clinical triage of Toxic epidermal necrolysis (TEN) (also termed Toxic epidermal necrolysis) (L51.2) in Skin & Dermatology relies on or targeted biologics [Toxic epidermal necrolysis (TEN) L51.2], guiding step-wise therapeutic adjustments toward 25-Hydroxy Vitamin D in Toxic epidermal necrolysis (TEN) (L51.2: & hs-CRP) (25(OH)D 40–65 ng/mL (L51.2)).
Pathophysiology, Underlying Causes & Clinical Presentation
Tissue-level etiology in Toxic epidermal necrolysis (TEN) (L51.2) features cutaneous immune skewing in Toxic epidermal necrolysis (TEN) (L51.2: (Th2/IL-4/IL-13 in atopic). therapeutic stabilization in skin & dermatology is verified against 25-Hydroxy Vitamin D in Toxic epidermal necrolysis (TEN) (L51.2: & hs-CRP).
Common Symptoms & Clinical Signs
- • Presentation of Toxic epidermal necrolysis (TEN) (L51.2): recurrent flares triggered in Toxic epidermal necrolysis (TEN) (L51.2: by UV exposure,)
- • Secondary Toxic epidermal necrolysis (TEN) clinical sign: persistent erythematous plaques, in Toxic epidermal necrolysis (TEN) (L51.2: scaly patches, pruritic)
- • Symptom flares in Toxic epidermal necrolysis (TEN) correlating with Fasting Lipids & in Toxic epidermal necrolysis (TEN) (L51.2: ALT (if systemic) deviation outside Within baseline reference limits (L51.2)
- • Functional skin & dermatology impact requiring or targeted biologics [Toxic epidermal necrolysis (TEN) L51.2] evaluation (L51.2)
Toxic epidermal necrolysis (TEN) Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | L51.2 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Dermatology: Acne, Eczema, Psoriasis & Rosacea | NLM Clinical Tables |
| Diagnostic / Lab Marker: Fasting Lipids & in Toxic epidermal necrolysis (TEN) (L51.2: ALT (if systemic) | Within baseline reference limits (L51.2) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: 25-Hydroxy Vitamin D in Toxic epidermal necrolysis (TEN) (L51.2: & hs-CRP) | 25(OH)D 40–65 ng/mL (L51.2) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Affected Body Surface in Toxic epidermal necrolysis (TEN) (L51.2: Area (BSA /) | Clear or Almost Clear (IGA 0–1) (L51.2) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Toxic epidermal necrolysis (TEN)
| Medication | Pharmacologic Class | Patient Worth-It | CMS NADAC / Unit | Typical Lowest Cash |
|---|---|---|---|---|
| Vectibix (Panitumumab) Vectibix • RxCUI RXN-B55513956 | Epidermal Growth Factor Receptor Antagonist | 91% | $0.6900 | $ 58.18 /mo |
| Panitumumab Vectibix • RxCUI RXN-55513956-3097 | Epidermal Growth Factor Receptor Antagonist | 85% | $1.5500 | $ 71.28 /mo |
| Cetuximab Erbitux • RxCUI 1657658 | Epidermal Growth Factor Receptor Antagonist | 91% | $0.4500 | $ 26.73 /mo |
| Methimazole Tapazole • RxCUI 197941 | Thyroid Hormone Synthesis Inhibitor | 80% | $0.0694 | $ 6.38 /mo |
| Erbitux (Cetuximab) Erbitux • RxCUI 1657660 | Epidermal Growth Factor Receptor Antagonist | 92% | $3.3900 | $ 252.58 /mo |
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Toxic epidermal necrolysis (TEN))
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Machine Learning Models of Early Longitudinal Toxicity Trajectories Predict: What a 376-Participant Study Found We used an innovative machine learning approach to analyze longitudinal joint drug toxicities, demonstrating their role in predicting patient outcomes through a putative how the body absorbs the medicine mechanism. JCO clinical cancer informatics • 2025-04-15 • Phase III Randomized Trial | N = 376 | 93/100 | PMID 40215447 ↗ |
| New Insights on Tazarotene 0.045% Lotion for Moderate-to-Severe Acne Patients: Pooled Phase 3: What a 1,013-Participant Study Found Tazarotene 0.045% lotion is efficacious and well tolerated in female and male adolescents and adults with moderate-to-severe acne. Journal of drugs in dermatology : JDD • 2021-06-01 • Phase III Randomized Trial | N = 1,013 | 90/100 | PMID 34076400 ↗ |
| New Insights on Concordance between clinician-reported toxicities and patient-reported symptom: What a 1,566-Participant Study Found Clinician-reported toxicities showed poor concordance with patient-reported symptom severity, and the discrepancy increased over time. ESMO open • 2026-05-15 • Phase III Randomized Trial | N = 1,566 | 90/100 | PMID 42215159 ↗ |
| New Insights on Early toxicity of moderately hypofractionated radiation therapy in breast cancer: What a 1,265-Participant Study Found Early AEs were mild and do not raise safety concerns for 3-week-RT in women receiving nodal RT. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology • 2025-06-15 • Phase III Randomized Trial | N = 1,265 | 90/100 | PMID 40097073 ↗ |
| Can This Approach Help? Inside the Latest Research on Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic Liraglutide reduces metabolic dysfunction, insulin resistance and lipotoxicity in the key metabolic organs in the pathogenesis of NASH. Journal of hepatology • 2016-02-15 • Randomized Controlled Trial | Multi-cohort | 88/100 | PMID 26394161 ↗ |
Toxic epidermal necrolysis (TEN) Patient Community & “People Like Me” Threads
Filter Toxic epidermal necrolysis (TEN) community threads and patient logs by age, biological sex, dosage, and treatment duration.